Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

46.7%

7 terminated/withdrawn out of 15 trials

Success Rate

36.4%

-50.1% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

175%

7 of 4 completed trials have results

Key Signals

2 recruiting7 with results7 terminated

Enrollment Performance

Analytics

Phase 1

12(85.7%)

Phase 2

2(14.3%)

14Total

Phase 1(12)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT06405633Phase 1Active Not Recruiting

A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD

Role: lead

NCT06186492Phase 1Completed

A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)

Role: lead

NCT07209332Phase 2Enrolling By Invitation

Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy

Role: lead

NCT06842186Phase 1Recruiting

A Phase 1 Study of WVE-007 in Adults Living With Overweight or Obesity

Role: lead

NCT04906460Phase 1Recruiting

Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Role: lead

NCT05032196Phase 1Completed

Study of WVE-003 in Patients With Huntington's Disease

Role: lead

NCT04931862Phase 1Terminated

Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)

Role: lead

NCT05683860Phase 1Terminated

Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)

Role: lead

NCT03225846Phase 1Terminated

Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

Role: lead

NCT03225833Phase 1Terminated

Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

Role: lead

NCT04617847Phase 1Terminated

Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

Role: lead

NCT04617860Phase 1Terminated

Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

Role: lead

NCT03907072Phase 2Terminated

Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy

Role: lead

NCT03508947Phase 1Completed

Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy

Role: lead

NCT03680365Completed

Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families

Role: collaborator

All 15 trials loaded